ECSP22008098A - Compuestos agonistas de gipr - Google Patents

Compuestos agonistas de gipr

Info

Publication number
ECSP22008098A
ECSP22008098A ECSENADI20228098A ECDI202208098A ECSP22008098A EC SP22008098 A ECSP22008098 A EC SP22008098A EC SENADI20228098 A ECSENADI20228098 A EC SENADI20228098A EC DI202208098 A ECDI202208098 A EC DI202208098A EC SP22008098 A ECSP22008098 A EC SP22008098A
Authority
EC
Ecuador
Prior art keywords
compounds
gipr
agonist compounds
useful
treatment
Prior art date
Application number
ECSENADI20228098A
Other languages
English (en)
Inventor
Andrea Renee Geiser
Hongchang Qu
John Lee
Jorge Alsina-Fernandez
William Christopher Roell
Lili Guo
Samantha Grace Lyons Keyser
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP22008098A publication Critical patent/ECSP22008098A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos que tienen actividad en el receptor de polipéptido insulinotrópico dependiente de glucosa (GIP) humano. La presente invención se refiere además a compuestos que tienen una duración de acción prolongada en el receptor de GIP. Tales compuestos pueden ser útiles en el tratamiento de la diabetes, que incluye diabetes mellitus tipo 2 ("T2DM"). Además, los compuestos pueden ser útiles en el tratamiento de la obesidad.
ECSENADI20228098A 2019-08-01 2022-02-01 Compuestos agonistas de gipr ECSP22008098A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962881685P 2019-08-01 2019-08-01

Publications (1)

Publication Number Publication Date
ECSP22008098A true ECSP22008098A (es) 2022-03-31

Family

ID=72145469

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20228098A ECSP22008098A (es) 2019-08-01 2022-02-01 Compuestos agonistas de gipr

Country Status (24)

Country Link
US (3) US11254721B2 (es)
EP (1) EP4007593A1 (es)
JP (3) JP7230272B2 (es)
KR (2) KR102801905B1 (es)
CN (2) CN114206915B (es)
AR (1) AR119471A1 (es)
AU (2) AU2020322784B2 (es)
CA (1) CA3145608A1 (es)
CL (1) CL2022000140A1 (es)
CO (1) CO2022000759A2 (es)
CR (1) CR20220020A (es)
DO (1) DOP2022000025A (es)
EC (1) ECSP22008098A (es)
IL (1) IL289463A (es)
JO (1) JOP20220024A1 (es)
MX (1) MX2022001137A (es)
MY (1) MY205796A (es)
NZ (1) NZ784648A (es)
PE (1) PE20220938A1 (es)
PH (1) PH12022550232A1 (es)
SA (1) SA522431576B1 (es)
TW (1) TWI764209B (es)
UA (1) UA129203C2 (es)
WO (1) WO2021021877A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI809515B (zh) * 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
JP7511548B2 (ja) * 2018-09-24 2024-07-05 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
TWI764209B (zh) * 2019-08-01 2022-05-11 美商美國禮來大藥廠 Gipr促效劑化合物
AR124295A1 (es) * 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
EP4281464A4 (en) 2021-01-20 2025-01-01 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
US20240360193A1 (en) * 2021-06-01 2024-10-31 Nanjing Zhihe Medicine Technology Co., Ltd. Polypeptide derivative with dual glp-1r and gipr targeting agonistic effect, and preparation method and use thereof
AU2022347024A1 (en) 2021-09-15 2024-05-02 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
IL319271A (en) 2022-08-29 2025-04-01 Lilly Co Eli Oral delivery preparations
KR102679905B1 (ko) * 2022-10-12 2024-07-02 서울대학교병원 Gipr 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
WO2024080650A1 (ko) * 2022-10-12 2024-04-18 서울대학교병원 Gipr 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
AU2024246525A1 (en) * 2023-03-31 2025-11-13 Eli Lilly And Company Methods and uses for treating nausea and emesis
CN116410298B (zh) * 2023-06-06 2023-08-11 诺博泰科(成都)生物科技有限公司 一种三激动多肽化合物及其盐、药用组合物、药剂和用途
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025161155A1 (zh) * 2024-02-04 2025-08-07 内蒙古博睿精创科技有限公司 一种长效glp-1多肽化合物、组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI689515B (zh) * 2012-05-03 2020-04-01 丹麥商西蘭製藥公司 Ｇｉｐ-ｇｌｐ-１雙重促效劑化合物及方法
EP3212218B1 (en) * 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
AR110301A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CR20210040A (es) * 2018-07-23 2021-02-12 Lilly Co Eli Compuestos coagonistas de gip/glp1
JP7511548B2 (ja) 2018-09-24 2024-07-05 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
US12122815B2 (en) 2018-09-24 2024-10-22 Takeda Pharmaceutical Company Limited GIP receptor agonist peptide compounds and uses thereof
TWI764209B (zh) * 2019-08-01 2022-05-11 美商美國禮來大藥廠 Gipr促效劑化合物

Also Published As

Publication number Publication date
MX2022001137A (es) 2022-02-16
JOP20220024A1 (ar) 2023-01-30
US11897926B2 (en) 2024-02-13
US11254721B2 (en) 2022-02-22
TW202126680A (zh) 2021-07-16
TWI764209B (zh) 2022-05-11
AU2020322784A1 (en) 2022-02-03
WO2021021877A1 (en) 2021-02-04
SA522431576B1 (ar) 2024-10-29
JP2022544061A (ja) 2022-10-17
NZ784648A (en) 2025-08-29
MY205796A (en) 2024-11-13
DOP2022000025A (es) 2022-03-15
CN114206915B (zh) 2025-03-11
US20210032299A1 (en) 2021-02-04
UA129203C2 (uk) 2025-02-05
AU2020322784B2 (en) 2025-01-30
IL289463A (en) 2022-02-01
JP7230272B2 (ja) 2023-02-28
KR20250065721A (ko) 2025-05-13
EP4007593A1 (en) 2022-06-08
BR112022000027A2 (pt) 2022-05-24
JP2024150523A (ja) 2024-10-23
JP7521027B2 (ja) 2024-07-23
CR20220020A (es) 2022-02-14
AU2025203018A1 (en) 2025-07-17
US20240218031A1 (en) 2024-07-04
US20220127315A1 (en) 2022-04-28
CA3145608A1 (en) 2021-02-04
CO2022000759A2 (es) 2022-02-07
CN114206915A (zh) 2022-03-18
CL2022000140A1 (es) 2022-09-30
PH12022550232A1 (en) 2023-01-04
JP2023062068A (ja) 2023-05-02
AR119471A1 (es) 2021-12-22
CN120040559A (zh) 2025-05-27
KR102801905B1 (ko) 2025-05-02
PE20220938A1 (es) 2022-05-31
KR20220028007A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
ECSP22008098A (es) Compuestos agonistas de gipr
MX2021000793A (es) Compuestos coagonistas de gip/glp1.
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
UA118239C2 (uk) Сполука-коагоніст gip і glp-1
NZ740644A (en) Glucagon receptor agonists
DOP2017000102A (es) Coagonistas de los receptores de glucagón y de glp-1
AR121093A1 (es) Compuestos coagonistas de gip / glp1
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
CL2009000173A1 (es) Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
EA201170302A1 (ru) Процессированные аналоги глюкозозависимого инсулинотропного полипетида
PE20151770A1 (es) Compuesto peptidico
EA201170304A1 (ru) Аналоги глюкозозависимого инсулинотропного полипептида
EA201170305A1 (ru) Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
EA201291234A1 (ru) Аналоги глюкагона
PE20161343A1 (es) Benzamidas sustituidas para el tratamiento de artropodos
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
MX2021012177A (es) Usos terapeuticos de dulaglutida.
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
ECSP17032341A (es) Coagonistas de los receptores de glucagón y de glp-1
TH2101000319A (th) สารประกอบอะโกนิสท์ร่วม gip/glp1